Nick Rodgers
Net worth: 39 845 $ as of 31/05/2026
Net worth: 39 845 $ as of 31/05/2026
Philip Nicholas Rodgers was the founder of Plutus Resources Plc, established in 2005, where the title held was Chief Executive Officer & Executive Director from 2012 to 2013.
Current jobs include Chairman-Designate at Cambridge Cognition Holdings Plc starting 2026, Director at Cambridge Meditech Ltd., Secretary, Financial Director & Director at Productiv Ltd. since 2011, and Director roles at Burvale Corporate Governance Advisory Ltd., Quickend Ltd., and Nick Rodgers Financial Ltd. Former jobs include Non-Executive Chairman at Destiny Pharma Plc from 2018 to 2023, Chairman at Sehta Enterprises Ltd. and Zpn Energy Ltd., Non-Executive Director at Oxford Biomedica Plc in 2016, Corporate Finance Director at Southampton Asset Management Ltd. from 2005 to 2007, Non-Executive Director at Morvus Technology Ltd., Director at Medermica Ltd., Non-Executive Director at TMO Renewables Ltd., Director at IPSol Energy Ltd., Accountant at Ernst & Young LLP, Head-Life Sciences & Corporate Finance at Evolution Securities Ltd. from 1989 to 2003, and Principal at Beeson Gregory Ltd.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 23/06/2026 | 79,892 ( 0.17% ) | 39 845 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| CAMBRIDGE COGNITION HOLDINGS PLC | Director/Board Member | 01/02/2024 |
Nick Rodgers Financial Ltd. | Director/Board Member | - |
Quickend Ltd. | Director/Board Member | - |
Cambridge Meditech Ltd.
Cambridge Meditech Ltd. Pharmaceuticals: MajorHealth Technology Manufactures wound infection detection products | Director/Board Member | - |
Burvale Corporate Governance Advisory Ltd. | Director/Board Member | - |
Productiv Ltd.
Productiv Ltd. Industrial ConglomeratesProducer Manufacturing Manufactures products for new low carbon technologies | Director of Finance/CFO | 12/04/2011 |
| Companies | Position | End |
|---|---|---|
Sehta Enterprises Ltd. | Chairman | 01/05/2024 |
| DESY PHAR | Chairman | 19/07/2023 |
| OXFORD BIOMEDICA PLC | Chairman | 01/02/2016 |
| ░░░░░░ ░░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 18 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Plutus Resources Plc
Plutus Resources Plc Financial ConglomeratesFinance Capital pool company | Finance |
Oxford Biomedica Plc
Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
Evolution Securities Ltd.
Evolution Securities Ltd. Investment ManagersFinance Provides securities brokerage services | Finance |
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance SAM works closely with the University to enhance development of their intellectual property. Through external partners, they develop spin-out firms, joint ventures and industry-led deals. They draw on the University's areas of expertise and have invested in ventures in oil and gas exploration, pharmaceuticals, nanotechnology and optoelectronics. Actual spin-out firms have been active in areas such as electromagnetic sensing services designed to detect the presence of offshore oil and gas, large-scale project management software, new methods for the synthesis of peptides and proteins, drug evaluation, testing and discovery in CNS disorders, photonic crystal technology, insect pest control solutions, optical solutions via laser wavelength conversion and integrated optical circuit technology, specialty optical fiber, cancer and heart disease drug treatment through histone deacetylase (HDAC) inhibitors, and gamma-ray detector systems. | Finance |
Beeson Gregory Ltd.
Beeson Gregory Ltd. Investment Banks/BrokersFinance Provides securities brokergae services | Finance |
Morvus Technology Ltd.
Morvus Technology Ltd. Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes of novel drugs and technologies in the oncology field | Health Technology |
Medermica Ltd.
Medermica Ltd. Electronic Equipment/InstrumentsElectronic Technology Develops diagnostic and sensor technologies for laboratory and healthcare applications | Electronic Technology |
Destiny Pharma Plc
Destiny Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops novel antimicrobial products | Health Technology |
Cambridge Meditech Ltd.
Cambridge Meditech Ltd. Pharmaceuticals: MajorHealth Technology Manufactures wound infection detection products | Health Technology |
TMO Renewables Ltd.
TMO Renewables Ltd. BiotechnologyHealth Technology Provides biological technology services | Health Technology |
Productiv Ltd.
Productiv Ltd. Industrial ConglomeratesProducer Manufacturing Manufactures products for new low carbon technologies | Producer Manufacturing |
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc Packaged SoftwareTechnology Services Provides cognitive assessment software for clinical trials, academic research and healthcare provision | Technology Services |
IPSol Energy Ltd.
IPSol Energy Ltd. Miscellaneous Commercial ServicesCommercial Services Provides business and technical solutions | Commercial Services |
Sehta Enterprises Ltd. | |
Burvale Corporate Governance Advisory Ltd. | |
Quickend Ltd. | |
Nick Rodgers Financial Ltd. |
Select your edition
All financial news and data tailored to specific country editions